Joanne Wuensch
Stock Analyst at Citigroup
(4.45)
# 243
Out of 4,778 analysts
390
Total ratings
62.31%
Success rate
12.43%
Average return
Main Sectors:
Stocks Rated by Joanne Wuensch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Buy | $115 → $110 | $84.07 | +30.84% | 20 | Mar 7, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $135 → $160 | $127.21 | +25.78% | 20 | Mar 4, 2025 | |
| DXCM DexCom | Maintains: Buy | $101 → $104 | $75.32 | +38.08% | 13 | Mar 4, 2025 | |
| SGHT Sight Sciences | Maintains: Neutral | $4.6 → $3 | $3.07 | -2.28% | 10 | Mar 4, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Neutral | $35 → $24 | $20.62 | +16.39% | 14 | Mar 4, 2025 | |
| MDT Medtronic | Upgrades: Buy | $92 → $107 | $90.13 | +18.72% | 19 | Mar 4, 2025 | |
| SYK Stryker | Reinstates: Buy | $450 | $374.27 | +20.23% | 13 | Feb 26, 2025 | |
| PODD Insulet | Maintains: Buy | $310 → $355 | $274.04 | +29.54% | 14 | Feb 21, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Buy | $103 → $110 | $81.70 | +34.64% | 3 | Feb 13, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $107 → $122 | $102.67 | +18.83% | 34 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $640 → $711 | $508.58 | +39.80% | 16 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $200 → $245 | $286.23 | -14.40% | 24 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $5 | $5.79 | -13.64% | 19 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $185 → $175 | $163.29 | +7.17% | 12 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $145 | $117.18 | +23.74% | 4 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $83 | $71.35 | +16.33% | 19 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $37 → $35 | $33.60 | +4.17% | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $7.5 | $7.37 | +1.76% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $22 | $15.91 | +38.28% | 4 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $132 → $162 | $107.61 | +50.54% | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $22 | $22.64 | -2.83% | 14 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $41.22 | +21.30% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $110 | $105.86 | +3.91% | 17 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $85 | $64.45 | +31.89% | 7 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $134 → $120 | $111.24 | +7.87% | 22 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $220 → $250 | $229.19 | +9.08% | 5 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $67 → $69 | $92.35 | -25.28% | 5 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $109 → $127 | $222.91 | -43.03% | 6 | Dec 10, 2018 |
The Cooper Companies
Mar 7, 2025
Maintains: Buy
Price Target: $115 → $110
Current: $84.07
Upside: +30.84%
Abbott Laboratories
Mar 4, 2025
Maintains: Buy
Price Target: $135 → $160
Current: $127.21
Upside: +25.78%
DexCom
Mar 4, 2025
Maintains: Buy
Price Target: $101 → $104
Current: $75.32
Upside: +38.08%
Sight Sciences
Mar 4, 2025
Maintains: Neutral
Price Target: $4.6 → $3
Current: $3.07
Upside: -2.28%
Tandem Diabetes Care
Mar 4, 2025
Downgrades: Neutral
Price Target: $35 → $24
Current: $20.62
Upside: +16.39%
Medtronic
Mar 4, 2025
Upgrades: Buy
Price Target: $92 → $107
Current: $90.13
Upside: +18.72%
Stryker
Feb 26, 2025
Reinstates: Buy
Price Target: $450
Current: $374.27
Upside: +20.23%
Insulet
Feb 21, 2025
Maintains: Buy
Price Target: $310 → $355
Current: $274.04
Upside: +29.54%
GE HealthCare Technologies
Feb 13, 2025
Maintains: Buy
Price Target: $103 → $110
Current: $81.70
Upside: +34.64%
Boston Scientific
Feb 6, 2025
Maintains: Buy
Price Target: $107 → $122
Current: $102.67
Upside: +18.83%
Jan 24, 2025
Maintains: Buy
Price Target: $640 → $711
Current: $508.58
Upside: +39.80%
Dec 11, 2024
Maintains: Neutral
Price Target: $200 → $245
Current: $286.23
Upside: -14.40%
Dec 11, 2024
Maintains: Neutral
Price Target: $6 → $5
Current: $5.79
Upside: -13.64%
Dec 11, 2024
Maintains: Buy
Price Target: $185 → $175
Current: $163.29
Upside: +7.17%
Dec 11, 2024
Maintains: Neutral
Price Target: $130 → $145
Current: $117.18
Upside: +23.74%
Dec 11, 2024
Maintains: Buy
Price Target: $81 → $83
Current: $71.35
Upside: +16.33%
Dec 11, 2024
Maintains: Neutral
Price Target: $37 → $35
Current: $33.60
Upside: +4.17%
Dec 11, 2024
Downgrades: Neutral
Price Target: $17 → $7.5
Current: $7.37
Upside: +1.76%
Dec 11, 2024
Downgrades: Neutral
Price Target: $24 → $22
Current: $15.91
Upside: +38.28%
Dec 11, 2024
Upgrades: Buy
Price Target: $132 → $162
Current: $107.61
Upside: +50.54%
Nov 5, 2024
Maintains: Sell
Price Target: $16 → $22
Current: $22.64
Upside: -2.83%
Oct 1, 2024
Maintains: Neutral
Price Target: $45 → $50
Current: $41.22
Upside: +21.30%
Aug 22, 2024
Maintains: Buy
Price Target: $135 → $110
Current: $105.86
Upside: +3.91%
Aug 22, 2024
Maintains: Neutral
Price Target: $94 → $85
Current: $64.45
Upside: +31.89%
Jul 10, 2024
Maintains: Neutral
Price Target: $134 → $120
Current: $111.24
Upside: +7.87%
Dec 12, 2022
Upgrades: Neutral
Price Target: $220 → $250
Current: $229.19
Upside: +9.08%
Nov 17, 2022
Maintains: Neutral
Price Target: $67 → $69
Current: $92.35
Upside: -25.28%
Dec 10, 2018
Upgrades: Outperform
Price Target: $109 → $127
Current: $222.91
Upside: -43.03%